The high-risk group presented a higher expression of PD1 (PDCD1), CTLA4, PD-L1 (CD274), and PD-L2 (PDCD1LG2), and our risk signature could also distinguish glioma patients with similar expression levels of immune checkpoints. This evidence concerns the gene PDCD1 and glioma.